search
Back to results

The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania

Primary Purpose

Bipolar Disorder

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
risperidone
Sponsored by
Janssen Korea, Ltd., Korea
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bipolar Disorder focused on measuring Bipolar, risperidone, Adjunctive therapy

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: In- or out-patient Diagnosis of bipolar I disorder most recent episode manic with or without psychotic features YMRS > 20 (manic) Need antipsychotic combination on the basis of clinicians' experience Exclusion Criteria: Rapid cycling Risk of suicide or violence History of Substance dependence within 3 months Comorbidities Unstable medical illness Previous sensitivity history to risperidone Pregnant woman or those without proper contraception History of clozapine and one cycle of depot use prior to entry History of treatment resistance: at least two mood stabilizers Prior history of active treatment with risperidone As for patients having wash-out period, patients that show 25% or more decrease in YMRS at baseline as compared to that at enrollment time, should be excluded.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    The change in YMRS score from baseline at 6 months

    Secondary Outcome Measures

    The change from baseline in Clinical Global Impression-Severity (CGI-S) score at 6 months; The change from baseline in HAMD score at 6 months

    Full Information

    First Posted
    September 13, 2005
    Last Updated
    January 20, 2011
    Sponsor
    Janssen Korea, Ltd., Korea
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00216554
    Brief Title
    The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania
    Official Title
    A Multicenter, Open-Label Study to Evaluate Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2011
    Overall Recruitment Status
    Completed
    Study Start Date
    September 2004 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    March 2006 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Janssen Korea, Ltd., Korea

    4. Oversight

    5. Study Description

    Brief Summary
    The purpose of this study is to evaluate effect of risperidone as a long-term combination therapy to mood stabilizers in the treatment of bipolar mania
    Detailed Description
    The use of mood stabilizers such as lithium and carbamazepine is known to be effective for preventing and treating bipolar disorder. But the use of antipsychotic drugs is more effective in patients suffering severe episodes of mania as it elicits behavioral changes and spurs the effects of mood stabilizers. Antipsychotic drugs are used for patients who failed to respond to mood stabilizers or for the acute management of manic episodes associated with bipolar disorders. This study aims to evaluate the safety and efficacy of risperidone as an adjunctive therapy to mood stabilizers in the long-term treatment (6months) of bipolar disorder using various assessment instruments, including the Young Mania Rating Scale. The Simpson-Angus Rating Scale will be also employed to assess the presence of extrapyramidal side effects and other adverse events. The patients will receive orally 0.5, 1, 2 mg risperidone tablet once daily for 6 months

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Bipolar Disorder
    Keywords
    Bipolar, risperidone, Adjunctive therapy

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    118 (Actual)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    risperidone
    Primary Outcome Measure Information:
    Title
    The change in YMRS score from baseline at 6 months
    Secondary Outcome Measure Information:
    Title
    The change from baseline in Clinical Global Impression-Severity (CGI-S) score at 6 months; The change from baseline in HAMD score at 6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: In- or out-patient Diagnosis of bipolar I disorder most recent episode manic with or without psychotic features YMRS > 20 (manic) Need antipsychotic combination on the basis of clinicians' experience Exclusion Criteria: Rapid cycling Risk of suicide or violence History of Substance dependence within 3 months Comorbidities Unstable medical illness Previous sensitivity history to risperidone Pregnant woman or those without proper contraception History of clozapine and one cycle of depot use prior to entry History of treatment resistance: at least two mood stabilizers Prior history of active treatment with risperidone As for patients having wash-out period, patients that show 25% or more decrease in YMRS at baseline as compared to that at enrollment time, should be excluded.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Janssen Korea, Ltd. Clinical Trial
    Organizational Affiliation
    Janssen Korea, Ltd.
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania

    We'll reach out to this number within 24 hrs